Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07152379

PHASE2

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Sponsor: Cerus Corporation

View on ClinicalTrials.gov

Summary

This study aims to determine whether transfusion of INTERCEPT RBCs into patients with pre-existing antibodies to INTERCEPT RBCs will result in increased antibody titer indicative of a secondary immune response, and whether these immune responses would be associated with clinical adverse events, increased RBC clearance, and/or evidence of hemolysis. Because the recovery and survival of fresh allogeneic INTERCEPT RBCs in patients with a diverse group of diseases is poorly characterized, a Control group of subjects without a history or evidence of antibodies to INTERCEPT RBCs may be evaluated as a comparator (Control group subjects may or may not have previously been transfused with INTERCEPT RBCs). The study will also compare and correlate results from anti-human globulin (AHG) crossmatch using INTERCEPT RBCs prepared for transfusion, with results from indirect antiglobulin testing (IAT) with S 303 treated reagent RBCs (i.e., INTERCEPT RBC screening assay, as used in previous studies) to assess the utility of the AHG crossmatch to define the compatibility of transfused INTERCEPT RBCs

Official title: An Open-label, Controlled Phase 2 Study Assessing a Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

Key Details

Gender

All

Age Range

4 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-01-01

Completion Date

2028-01-01

Last Updated

2025-09-03

Healthy Volunteers

Conditions

Transfusion Reaction, Hemolytic

Interventions

DEVICE

INTERCEPT RBCs

Transfusion of fresh (≤14 days old) allogeneic INTERCEPT RBCs.

Inclusion Criteria: * Age ≥4 years in children who meet the requirement of US Code of Federal Regulation (CFR) Title 21, §50.53 as determined by the local Institutional Review Board (IRB). * Control subjects shall have no current or previously documented antibodies to INTERCEPT RBC. * Test subjects shall have current or previously documented natural or treatment-emergent antibodies to INTERCEPT RBCs. * History of prior transfusion with allogeneic blood products (INTERCEPT or non-INTERCEPT treated). * \>120 days from the subjects most recent exposure to Study RBCs (pathogen reduced or non-pathogen reduced - if any) prior to the planned study transfusion. * Signed and dated informed consent form Exclusion Criteria: * Foreseeable active blood loss due to trauma, surgery, or pathologic condition during the study period. * Exposure to another interventional drug or device in a clinical study within 28 days prior to enrollment or concurrently during the study. * Positive Direct Antiglobulin Test (≥2+) at the time of screening, prior to the first study transfusion. * Current or historical medical conditions judged by the Investigator to significantly increase the risk of morbidity/mortality due to hemolysis or the medical management of acute hemolysis. * Treatment with any medication known to affect RBC viability at the time of enrollment (e.g., ribavirin, sulfa drugs, chemotherapy medications, methylene blue, dapsone, levodopa, methyldopa, nitrofurantoin and its derivatives, phenazopyridine, quinidine, and hydantoins) * History of or development of a drug-associated RBC antibody not associated with INTERCEPT RBCs. * Congenital or acquired immunodeficiency judged by the Investigator to potentially impact the humoral immune response. * Immunosuppressive therapy within 1 month prior to enrollment or during the study period, including steroids and intravenous immunoglobulin. * Current or historical RBC alloantibodies that are judged by the Investigator to prevent selection of antigen-negative RBCs for transfusion. * History of immunoglobulin A (IgA) deficiency, severe allergic reaction to blood product(s), or clinical requirement to receive washed cellular products. * History of warm autoantibody with hemolysis. * Subjects who are pregnant, or biologically able to become pregnant and unwilling to remain on medically accepted contraception during this study.